Aptar Pharma Forms Pact with BD to Develop Novel Autoinjector

Published on: 

Aptar Pharma has signed a license agreement with BD to jointly develop and bring a new autoinjector to market.

Drug-delivery solutions provider Aptar Pharma, part of AptarGroup, announced that it has signed an exclusive development and license agreement with BD (Becton, Dickinson and Company), a medtech firm, to jointly develop a novel auto-injector using Aptar Pharma’s high-performance, two-step autoinjector technology and prefillable syringes from BD.

Based on feedback from patients and healthcare professionals in a market research conducted by Aptar Pharma, the company will work together with BD to create and optimize a compact device that delivers highly viscous drugs, including some of the new biologics. Aptar Pharma’s autoinjector technology has been designed around the BD Neopak 1-mL long glass prefillable syringe or the BD Hypak for Biotech 1-mL long glass prefillable syringe to optimize robustness and performance of the system.

Under the agreement, Aptar and BD will jointly develop Aptar Pharma’s autoinjector technology platform using BD’s expertise in prefillable syringes and self-injection technologies combined with Aptar Pharma’s innovation and quality-by-design expertise. The two-step autoinjector will be exclusively commercialized by BD as part of their portfolio of autoinjectors.


Source: Aptar Pharma